Research Makes A Difference

Research is essential to the development of effective disease treatments.

The mortality rate of Hodgkin lymphoma has significantly decreased over the past 25 years due to advancements in treatment. (National Cancer Institute, August 2005

New treatment options such as Rituximab have helped to improve patient outcomes. (National Cancer Institute, June 2004)

Cancer death rates dropped by 1.1% per year from 1993 to 2002 thanks to advancements in prevention, early detection, and treatment. (National Cancer Institute, October 2005)


Finding a cure; developing treatments; improving care

These are fundamental to the Lymphoma Research Foundation (LRF). To accomplish these essentials, research is vital.

LRF's research program has grown significantly in recent years. Guided by our Scientific Advisory Board, a body of leading lymphoma specialists, LRF has developed a research strategy based on models that single out specific lymphomas. Our first model was built to research Mantle Cell Lymphoma (MCL), which began with the establishment of the MCL Initiative in 2003, and enhanced by the MCL Consortium (MCLC) in 2005. This groundbreaking initiative has concentrated 24 research teams in the U.S., Canada, and Europe, and currently has over 100 members.

Outcomes of the MCLC have included an annual members' workshop; a special Web site and Intranet that enables researchers to easily share progress and discoveries; a cell line bank in development, and "correlative" grants meant to enhance the quality of findings from ongoing clinical trials.

With the MCL model successfully underway, LRF is pursuing two other programs focused on Follicular Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Fundraising successes in these areas will enable LRF to create comprehensive, large-scale programs. 

LRF runs multiple research programs, grants, and awards. Below is a brief overview of each with links to more detailed information.


LRF awards grants in a number of key areas:

  1. Training and recruiting junior researchers: Fellowships and Clinical Investigator Career Development Awards
  2. Focus Area Grants

Special Research Programs

With the support of generous donors, LRF has been able to turn a spotlight on Mantle Cell Lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (formerly referred to as non-Hodgkin's lymphoma) that is challenging to treat. Although MCL accounts for only about 5% to 10% of all lymphomas, the orphan nature of the disease suggested a need to focus research attention with an innovative program. Click here to learn more about the MCL Consortium and MCL.

The LRF sees the MCL Grants and the Consortium Program as a model for similar future efforts in other subtypes of both NHL and HL.

Professional Education

LRF also works to help physicians and nurses keep abreast of important developments in patient care, the most recent findings on new pharmaceuticals, and new drug protocols designed to maximize the benefits of already existing drugs. Check out the latest Professional Education opportunities.

Scientific Advisory Board

Members of LRF's Scientific Advisory Board are key leaders in blood cancer research with outstanding experience and accomplishments in both lymphoma specific research and clinical care. They guide the planning of LRF's research and educational programs, advocacy activities, and select and track grant recipients.

LRF's Scientific Advisory Board has adopted a statement of Core Values and Goals through 2008 for the Research Program.


News from LRF's Research Department can be found in our newsletter, Research Report, which is published 3-4 times yearly. Content ranges from coverage of scientific workshops, grantee accomplishments and other news from the field of lymphoma research. Our most current issue and archived issues are always available for download in pdf format.